<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="350">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02140372</url>
  </required_header>
  <id_info>
    <org_study_id>S13-00747</org_study_id>
    <nct_id>NCT02140372</nct_id>
  </id_info>
  <brief_title>Anti-platelet Effects of Colchicine in Healthy Volunteers</brief_title>
  <official_title>Anti-platelet Effects of Colchicine in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York University School of Medicine</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study. Volunteers will be given 1.8 mg (1.2 mg followed by 0.6 mg one hour
      later), 1.2 mg, or 0.6 mg of colchicine. Blood will be collected prior to drug
      administration, 2 hours after colchicine administration, and 24 hours after colchicine
      administration via the antecubital vein and evaluated for markers of platelet activity and
      inflammation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Monocyte Platelet Aggregate: Baseline</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Monocyte Platelet Aggregate: 2 Hours</measure>
    <time_frame>2 Hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Light Transmission Aggregometry: Baseline</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>In response to adenosine diphosphate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Light Transmission Aggregometry: 2 Hours</measure>
    <time_frame>2 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>In response to adenosine diphosphate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Light Transmission Aggregometry: Baseline</measure>
    <time_frame>baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>In response to adenosine epinephrine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Light Transmission Aggregometry: 2 Hours</measure>
    <time_frame>2 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>In response to adenosine epinephrine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet Adhesion: Baseline</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet Adhesion: 2 Hours</measure>
    <time_frame>2 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Volunteer group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Baseline blood draw followed by colchicine followed by blood draw 2 hours and 24 hours later</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colchicine</intervention_name>
    <description>Colchicine 1.2 mg followed by 0.6 mg one hour later</description>
    <arm_group_label>Volunteer group</arm_group_label>
    <other_name>Colcrys</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must be more than 18 years of age

        Exclusion Criteria:

        1) history of cardiovascular disease, including myocardial infarction, history of
        percutaneous coronary angioplasty or stent, peripheral vascular disease or stroke; 2)
        history of myelodysplasia; 3) medications known to affect platelet function, including
        non-steroidal anti-inflammatory drugs, antihistamines, and selective serotonin reuptake
        inhibitors, during the 5 days prior to participation; 4) medications known to interact
        with colchicine; 5) history of intolerance to colchicine; 6) acute or chronic symptoms of
        diarrhea, nausea, or vomiting within 1 month prior to enrollment; 7) known anemia or
        hemoglobin &lt;10mg/dL; 8) platelet count &lt;100,000 or &gt; 450,000; 9) creatinine clearance
        &lt;30cc/minute; 10) any known hemorrhagic diathesis; 11) pregnant; 12) Unable to consent; or
        13) Participating in a competing study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Binita Shah, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU SOM</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <lastchanged_date>January 26, 2016</lastchanged_date>
  <firstreceived_date>May 14, 2014</firstreceived_date>
  <firstreceived_results_date>January 26, 2016</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>colchicine</keyword>
  <keyword>platelet activity</keyword>
  <keyword>neutrophil</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colchicine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Volunteer Group</title>
          <description>Baseline blood draw followed by colchicine followed by blood draw 2 hours and 24 hours later
Colchicine: Colchicine 1.2 mg followed by 0.6 mg one hour later</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Volunteer Group</title>
          <description>Baseline blood draw followed by colchicine followed by blood draw 2 hours and 24 hours later
Colchicine: Colchicine 1.2 mg followed by 0.6 mg one hour later</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="4"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Hispanic or Latino</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Not Hispanic or Latino</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>American Indian or Alaska Native</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Native Hawaiian or Other Pacific Islander</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Black or African American</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>More than one race</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Monocyte Platelet Aggregate: Baseline</title>
        <time_frame>Baseline</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Volunteer Group</title>
            <description>Baseline blood draw followed by colchicine followed by blood draw 2 hours and 24 hours later
Colchicine: Colchicine 1.2 mg followed by 0.6 mg one hour later</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Monocyte Platelet Aggregate: Baseline</title>
            <units>percentage of monocyte-platelet aggregat</units>
            <param>Median</param>
            <dispersion>Inter-Quartile Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="27.8" lower_limit="21.6" upper_limit="57.3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Light Transmission Aggregometry: Baseline</title>
        <description>In response to adenosine diphosphate</description>
        <time_frame>Baseline</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Volunteer Group</title>
            <description>Baseline blood draw followed by colchicine followed by blood draw 2 hours and 24 hours later
Colchicine: Colchicine 1.2 mg followed by 0.6 mg one hour later</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Light Transmission Aggregometry: Baseline</title>
            <description>In response to adenosine diphosphate</description>
            <units>percentage of max platelet aggregation</units>
            <param>Median</param>
            <dispersion>Inter-Quartile Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="48.7" lower_limit="33.5" upper_limit="85.3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Monocyte Platelet Aggregate: 2 Hours</title>
        <time_frame>2 Hours</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Volunteer Group</title>
            <description>Baseline blood draw followed by colchicine followed by blood draw 2 hours and 24 hours later
Colchicine: Colchicine 1.2 mg followed by 0.6 mg one hour later</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Monocyte Platelet Aggregate: 2 Hours</title>
            <units>percentage of monocyte-platelet aggregat</units>
            <param>Median</param>
            <dispersion>Inter-Quartile Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="22" lower_limit="19.0" upper_limit="30.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Light Transmission Aggregometry: 2 Hours</title>
        <description>In response to adenosine diphosphate</description>
        <time_frame>2 hours</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Volunteer Group</title>
            <description>Baseline blood draw followed by colchicine followed by blood draw 2 hours and 24 hours later
Colchicine: Colchicine 1.2 mg followed by 0.6 mg one hour later</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Light Transmission Aggregometry: 2 Hours</title>
            <description>In response to adenosine diphosphate</description>
            <units>percentage of max platelet aggregation</units>
            <param>Median</param>
            <dispersion>Inter-Quartile Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="66.6" lower_limit="23.6" upper_limit="87.3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Light Transmission Aggregometry: Baseline</title>
        <description>In response to adenosine epinephrine</description>
        <time_frame>baseline</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Volunteer Group</title>
            <description>Baseline blood draw followed by colchicine followed by blood draw 2 hours and 24 hours later
Colchicine: Colchicine 1.2 mg followed by 0.6 mg one hour later</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Light Transmission Aggregometry: Baseline</title>
            <description>In response to adenosine epinephrine</description>
            <units>percentage of max platelet aggregation</units>
            <param>Median</param>
            <dispersion>Inter-Quartile Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="84.9" lower_limit="61.8" upper_limit="90.2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Light Transmission Aggregometry: 2 Hours</title>
        <description>In response to adenosine epinephrine</description>
        <time_frame>2 hours</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Volunteer Group</title>
            <description>Baseline blood draw followed by colchicine followed by blood draw 2 hours and 24 hours later
Colchicine: Colchicine 1.2 mg followed by 0.6 mg one hour later</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Light Transmission Aggregometry: 2 Hours</title>
            <description>In response to adenosine epinephrine</description>
            <units>percentage of max platelet aggregation</units>
            <param>Median</param>
            <dispersion>Inter-Quartile Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="84.6" lower_limit="48.6" upper_limit="87.7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Platelet Adhesion: Baseline</title>
        <time_frame>Baseline</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Volunteer Group</title>
            <description>Baseline blood draw followed by colchicine followed by blood draw 2 hours and 24 hours later
Colchicine: Colchicine 1.2 mg followed by 0.6 mg one hour later</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Platelet Adhesion: Baseline</title>
            <units>percentage of adhered platelets</units>
            <param>Median</param>
            <dispersion>Inter-Quartile Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10.2" lower_limit="2.5" upper_limit="32.6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Platelet Adhesion: 2 Hours</title>
        <time_frame>2 hours</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Volunteer Group</title>
            <description>Baseline blood draw followed by colchicine followed by blood draw 2 hours and 24 hours later
Colchicine: Colchicine 1.2 mg followed by 0.6 mg one hour later</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Platelet Adhesion: 2 Hours</title>
            <units>percentage of adhered platelets</units>
            <param>Median</param>
            <dispersion>Inter-Quartile Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2.0" lower_limit="0.2" upper_limit="9.5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Volunteer Group</title>
          <description>Baseline blood draw followed by colchicine followed by blood draw 2 hours and 24 hours later
Colchicine: Colchicine 1.2 mg followed by 0.6 mg one hour later</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Binita Shah</name_or_title>
      <organization>NYU School of Medicine</organization>
      <phone>212-263-4235</phone>
      <email>binita.shah@nyumc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
